T A B L E O F C O N T E N T S

Selection criteria
Randomised trials in adults after stroke where the intervention was specifically targeted at improving the eye movement disorder or improving the ability of the participant to cope with the eye movement disorder. The primary outcome was functional ability in activities of daily living. Secondary outcomes included functional ability in extended activities of daily living, eye movement measures, balance, falls, depression or anxiety, discharge destination or residence after stroke, quality of life and social isolation, adverse events, and death.
Data collection and analysis
Two authors independently screened abstracts, extracted data and appraised trials. We undertook assessment of methodological quality for allocation concealment, blinding of outcome assessor, method of dealing with missing data, and other potential sources of bias.
Main results
Two studies (28 participants but only five were people with stroke) met the inclusion criteria and were included in this review. Both studies investigated pharmacological interventions for disorders of eye movement in patients with stroke. It was not appropriate to pool data and we were not able to draw conclusions from these studies. We found no other randomised studies which investigated interventions for disorders of eye movement in patients with stroke.
Authors' conclusions
There is insufficient evidence to reach conclusions about the effectiveness of interventions for patients with eye movement disorders after stroke. High quality research in the form of well-designed randomised trials are urgently required.
P L A I N L A N G U A G E S U M M A R Y
Interventions for eye movement disorders in people with stroke
Eye movement disorders may affect over 70% of stroke patients and can make it difficult to keep both eyes in their normal position when looking straight ahead, or can make it difficult to move the eyes accurately to look in a different direction. This can affect patients' perception of depth, makes it difficult for them to take in their whole surroundings and can severely affect the ability to read. We found only two randomised controlled trials which investigated treatments for eye movement disorders. Both of these studies investigated the effect of drug treatments. A total of 28 participants were included but only five of these were people with stroke. One study found that the people with stroke responded differently to the drug treatment than people who had eye movement disorders due to other conditions. These studies provide too little evidence from which to reach any conclusions about the effectiveness of interventions for patients with eye movement disorders after stroke. Further research is urgently required.
B A C K G R O U N D
The association between visual impairment and disability in activities of daily living is well established (Wolter 2006) . The services available to patients with visual problems following stroke are inconsistent at present. We aim to provide an evidence base to facilitate the development of further research and promote best treatments for patients with visual problems following stroke.
This review is one of a series of reviews being supported by the Royal National Institute for the Blind (RNIB). The aim of these reviews is to identify the evidence base for treatments of visual problems following stroke. The project team aims to develop appropriate primary research proposals on completion of these reviews.
Description of the condition
Disorders of eye movements are caused by damage to the extraocular muscle, the cranial nerves supplying the ocular muscles, or to the neural pathways that control these nerves. It has been reported that in symptomatic patients up to 86% of those with stroke or non-traumatic acquired brain injury have eye movement disorders (Ciuffreda 2007; Rowe 2009a) and in a general population of stroke patients, at various stages of recovery, between 7% and 55% have eye movement disorders (Clisby 1995; Freeman 1987; MacIntosh 2003) . These disorders can cause a variety of problems (Jones 2006; Pederson 1981; Rowe 2009a) including the following difficulties and eye movements.
Difficulties in maintaining the normal ocular position
• Conjugate eye deviation: both eyes turn constantly to one side.
• Strabismus: one eye deviates horizontally or vertically, or both, with or without the eye rotating away from the straight position so the eyes are no longer aligned.
• Nystagmus: frequent involuntary oscillations and other random eye movements.
Difficulty with moving eyes appropriately
• Saccades: fast movements that carry the eye from one target to another.
• Pursuits: slow movements that allow a moving object to be followed.
• Fixation: ability to maintain steady eye position on a target.
• Convergence: ability of the eyes to turn in to focus on near objects.
• Divergence: ability of the eyes to turn out and focus on distant objects.
• Vestibulo-ocular reflex: movement of the eyes in response to a quick head movement.
• Palsy: inability to use one or more of the muscles that move the eye up, down, left or right.
The result is a range of functional disabilities. These include a loss of depth perception, reduced hand-to-eye co-ordination and marked difficulties with near tasks and reading (MacIntosh 2003) . Reduced ability to scan the visual environment may affect visual memory, recognition, the ability to formulate plans and decision making (Wolter 2006) . The disorders may also impact on the effectiveness of rehabilitation therapy in regaining mobility and activities of daily living (MacIntosh 2003), and have an impact on quality of life (Ciuffreda 2008).
Description of the intervention
There are a number of different treatment and management approaches available to patients with eye movement disorders. This review considers any intervention that is specifically targeted at improving the disorder, or improving the ability of the patient to cope with it. Treatments for eye movement disorders can be described as restitution, compensation or substitution (Kerkhoff 2000) . In addition to these types of treatments, this review will also consider assessment and screening interventions that are specifically targeted at patients with eye movement disorders. These interventions may include, but not be limited to, the following.
• Restitutive interventions: convergence training, pursuit training, saccade training.
• Compensative interventions: training eye movements for reading, compensatory head posture or movements, use of eye blinks or colour cues, training in activities of daily living.
• Substitutive interventions: prisms, eye patches, injections and surgery, magnification, environmental modification.
• Assessment and screening interventions: standardised visual assessment, screening and referral for visual assessment and intervention, assessment of different types of eye movement.
How the intervention might work Restitution
Restitution includes the biochemical events that help restore functional neural tissue: the reduction of oedema, absorption of blood, restoration of normal neuronal physiology and restoration of axon transport. In the past it has been thought that restitutive approaches would have limited effect in visual rehabilitation. However, treatments of convergent fusion and stereopsis through repetition training of the deficient function have been reported as effective (Kerkhoff 2000) . Restitutive interventions include those where there is direct training of the impaired function or repetitive stimulation of eye movement.
Compensation
Compensation aims to improve the mismatch between the patients' skills and the demands placed on them by their environment by teaching them to compensate using a spared or intact function (Kerkhoff 1999; Kerkhoff 2000) .
Substitution
Substitution involves adaptation of visual components that have been lost or disrupted through the use of optic devices or environmental modifications (Kerkhoff 1999; Kerkhoff 2000).
Assessment and screening interventions
These may work by ensuring that the eye movement disorder is appropriately diagnosed, which enables other interventions to be prescribed or enables patients to be given advice and education about the management of their condition and adaptation of their environment.
The interventions for eye movement disorders are therefore proposed to work by either restoring the eye movement (restitution); compensating for the eye movement disorder by changing behaviour or activity (compensation); substituting for the eye movement disorder by using a device or extraneous modification (substitution); or ensuring appropriate diagnosis, referral and treatment prescription through standardised assessment or screening, or both.
Why it is important to do this review
Eye movement disorders are relatively common after stroke. They can result in wide-ranging functional difficulties (Rowe 2009a; Rowe 2009b) and may negatively impact on rehabilitation after stroke. There are a wide variety of different treatment interventions proposed for eye movement disorders after stroke. The body of evidence relating to eye movement disorders is growing. However, in the past, there has been a lack of evidence specific to the impact of interventions on the functional outcome of patients with stroke (Ciuffreda 2008). There are two recent published reviews of the literature relating to visual problems following stroke (Jones 2006; Wolter 2006) . Both of these reviews provide a broad overview of the literature relating to visual problems after stroke but do not provide a rigorous, systematic analysis of outcomes of treatment interventions for eye movement disorders. Two reviews (Barrett 2009; Riggs 2007) were completed but with a number of methodological limitations. Neither review identified primary evidence relating to eye movement disorders in patients with stroke. A high-quality systematic review of the existing evidence base is essential in order to determine the evidence for the effectiveness of any treatment or management approaches for stroke patients with eye movement disorders. This review will also facilitate appropriate planning and prioritisation of future primary research.
O B J E C T I V E S
Research question
Do interventions for eye movement disorders improve functional ability following stroke?
Specific objectives
1. To determine whether, in patients with eye movement disorders following stroke: i) restitutive interventions are more effective than control, placebo or no intervention at improving functional ability in activities of daily living;
ii) compensative interventions are more effective than control, placebo or no intervention at improving functional ability in activities of daily living;
iii) substitutive interventions are more effective than control, placebo or no intervention at improving functional ability in activities of daily living; iv) assessment and screening interventions are more effective than standard care at improving functional ability in activities of daily living.
2. To determine whether, in patients with eye movement disorders following stroke: i) restitutive interventions are more effective than control, placebo or no intervention at improving secondary outcomes;
ii) compensative interventions are more effective than control, placebo or no intervention at improving secondary outcomes;
iii) substitutive interventions are more effective than control, placebo or no intervention at improving secondary outcomes;
iv) assessment and screening interventions are more effective than standard care at improving secondary outcomes.
3. To explore the relationship between patient characteristics and the effect of interventions aimed at improving functional abilities in activities of daily living by using subgroup analysis. 4. To make specific recommendations for future research into the effectiveness of interventions for eye movement disorders based on a knowledge of the existing evidence base.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and randomised controlled cross-over trials (analysing the first phase as a parallel group trial).
Types of participants
Adult participants (over 18 years of age) after stroke (using the World Health Organization (WHO) definition of stroke, or a clinical definition if not specifically stated, that is, signs and symptoms persisted longer than 24 hours) and with a clinical diagnosis of an eye movement disorder. The eye movement disorder must have occurred as a direct result of the stroke. We accepted studies that included participants based on symptoms which can be assumed to be present as a direct result of an eye movement disorder.
These symptoms include double vision, difficulty reading, blurred vision, wobbling vision, and excessive head movements. We documented the type of eye movement disorder and planned to conduct subgroup analysis to investigate the effect of each type. If possible, we documented the type of eye movement disorder (III, IV, and VI nerve palsy; reduced fixation or gaze holding; saccadic palsy or problems; smooth pursuit palsy or problems; strabismus; nystagmus; reduced convergence; conjugate deviation; skew deviation), the deviation of eye movement (horizontal, vertical, torsional), and the severity of eye movement disorder (slight, small, moderate, marked; paralysis or paresis; monocular or binocular) and planned to investigate the effects via further subgroup analyses.
Types of interventions
We included any intervention that was specifically targeted at improving the defects of eye movement or improving the ability of the patient to cope with the disorder. We planned to classify interventions as either restitution, compensation, substitution, or assessment and screening. We compared interventions with a no treatment, placebo or a control intervention, or against standard care. We planned four specific comparisons: (1) restitutive interventions versus no treatment, placebo or control; (2) compensative interventions versus no treatment, placebo or control; (3) substitutive interventions versus no treatment, placebo or control; and (4) assessment and screening interventions versus standard care. We identified an additional comparison following the selection of included trials: (5) pharmacological interventions versus no treatment, placebo or control. We documented a description of the placebo or control intervention, or standard care. We accept as standard care any 'normal', 'routine' or 'usual' care as defined by the researchers.
Types of outcome measures
If possible, we assessed the outcome at the end of the intervention period and at a follow-up point (ideally six months after the completion of the intervention).
Primary outcomes
Functional ability in activities of daily living
We included studies using the following validated scales: Barthel Activities of Daily Living Index (Mahoney 1965), Functional Independence Measure (FIM) (Smith 1990), Modified Rankin Scale, Katz Index of Activities of Daily Living (Katz 1963), and the Rehabilitation Activities Profile. If a study reported more than one of these functional ability scales, we used the scale listed earliest in this list.
Secondary outcomes
Functional ability in extended activities of daily living
Nottingham Extended Activities of Daily Living scale, Lawton Instrumental Activities of Daily Living, Frenchay Activities Index (Holbrook 1983), Rivermead ADL score.
Eye movement
From orthoptic tests, including size of deviation, gradation of movements, severity of disorder (slight, small, moderate, marked; paralysis or paresis; monocular or binocular).
Balance
Berg Balance Scale (Berg 1989), Functional Reach (Duncan 1990), Get Up and Go Test (Mathias 1986), Standing Balance Test, Step Test or other standardised balance measure. We did not include measures of weight distribution or postural sway during standing as it was not possible for us to establish the relationship between the ability to maintain balance and these outcomes.
Falls
Number of reported falls, Falls Efficacy Scale (Tinetti 1990).
Depression and anxiety
Hospital Anxiety and Depression Scale, Beck Depressive Inventory, General Health Questionnaire, Geriatric Depression Scale.
Discharge destination or residence after stroke
Dichotomous variable: discharged to previous place of residence (that is, place of residence prior to stroke) or discharged to alternative destination.
Electronic searches
We searched the Cochrane Stroke Group Trials Register (February 2011), the Cochrane Eyes and Vision Group Trials Register (December 2009), and the following electronic bibliographic databases: 
Searching other resources
In an effort to identify further published, unpublished and ongoing trials, we undertook the following. 5. Searched the reference lists of included trials and review articles about vision after stroke.
6. Contacted experts in the field (including authors of included trials and excluded studies identified as possible preliminary or pilot work). We searched for trials in all languages and arranged for translation of trials published in languages other than English.
Data collection and analysis
One review author (CH) ran all the electronic searches, downloaded references into bibliographic software, and removed duplicates. One review author (CH) excluded any titles which were obviously not related to stroke and vision. We obtained the abstracts for any references related to stroke and vision. Two review authors (CH, AP) independently considered each of these abstracts, excluded any studies which were clearly not RCTs or cross-over trials, and excluded any studies where the intervention was not specifically aimed at improving the eye movement disorder or the patient's ability to cope with the eye movement disorder. We resolved any disagreements through discussion. We obtained the full papers for any studies included at this stage.
Selection of studies
Two review authors (CH, AP) independently applied the selection criteria, considering and documenting the type of studies, type of participants, intervention, comparison intervention, and the outcome measures. Each review author classified each study as include or exclude. If there was disagreement between these two review authors, they reached consensus through discussion involving a third review author. We listed any excluded studies that included participants with eye movement disorders in the Characteristics of excluded studies table, with the reason for exclusion. We did not list in the Characteristics of excluded studies table studies that were excluded because they included participants that did not have eye movement disorders (that is, visual neglect, age-related visual problems, or visual field loss) unless the two review authors agreed that there was a clear reason to do so.
Data extraction and management
We used a pre-designed data extraction form to record data from the included studies. Two review authors (CH, AP) independently documented the following.
• Methods: study design, method of randomisation.
• Participants: number of participants, inclusion criteria. We documented the method of diagnosing the eye movement disorder. We recorded the country of origin of participants.
• Interventions: description of interventions given to each treatment group including, if relevant, the duration, intensity, frequency, or dose. We classified the type of intervention as restitution, compensation, substitution, or assessment and screening, and the type of control as no treatment, placebo, control, or standard care. We documented the professional background of the person providing the intervention (e.g. occupational therapist, orthoptist).
• Outcomes: we documented the primary and secondary outcomes relevant to this review. If a study used a number of different methods of measuring the same outcome, we noted the outcome to be used for any subsequent analysis.
• Notes: we recorded any important confounding variables. If a study included more than two intervention groups, we also recorded the method of including these groups in any subsequent analysis.
In addition, the review authors independently documented, if data allowed, the following demographics of the included participants: age, gender, place of residence, type of stroke, side of stroke, time since stroke, initial eye movement disorders, and initial functional ability. If there were any discrepancies between data extracted by the two review authors, these were resolved through discussion.
Assessment of risk of bias in included studies
We assessed risk of bias by answering the following questions for each included study, and documenting this within the 'Risk of bias' tables.
Was allocation adequately concealed?
Studies with adequate concealment included those which used central randomisation at a site remote from the study, computerised allocation in which records were in a locked readable file accessible only after entering patient details, or the drawing of opaque envelopes. Studies with inadequate concealment included those using an open list or a table of random numbers, open computer systems, or the drawing of non-opaque envelopes. Studies with unclear concealment included those with no or inadequate information in the report.
Was knowledge of the allocated intervention adequately concealed from the outcome assessor?
We considered studies to be adequately concealed if the outcome assessor was masked and the report did not identify any unmasking. We considered studies inadequately concealed if the outcome assessor was not masked or where the report clearly identified that unmasking occurred during the study. We documented concealment as unclear if a study did not state whether or not an outcome assessor was masked or there was insufficient information to judge.
Were incomplete outcome data adequately addressed?
Studies that adequately addressed incomplete outcome data had: no missing outcome data; missing outcome data which were unlikely to be related to a true outcome; missing outcome data which were balanced in numbers across intervention groups, with similar reasons for missing data across the groups; a reported effect size (difference in means or standardised difference in means) among missing outcomes which were not enough to have a clinically relevant impact on observed effect size; or missing data which had been imputed using appropriate methods. Studies which inadequately addressed incomplete outcome data had: missing outcome data which were likely to be related to a true outcome, with either an imbalance in numbers or reasons for missing data across intervention groups; a reported effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; or as-treated analysis done with substantial departure of the intervention received from that assigned at randomisation. We documented the addressing of incomplete outcome data as unclear if there was insufficient reporting to allow this to be assessed, or if this was not addressed in the report.
Was the study apparently free of other problems that could put it at a high risk of bias?
We assessed a study not to be free of bias if it was assessed to have at least one important risk of bias, such as a potential source of bias related to the specific study design used; an extreme baseline imbalance; a claim to have been fraudulent; or some other problem. If there was insufficient information, or the information provided was unclear, we documented the risk of other bias as unclear. We produced a 'Risk of bias' summary figure to illustrate the potential biases within each of the included studies.
Measures of treatment effect
We planned to use Review Manager 5 (RevMan 2011) to carry out statistical analyses to determine the treatment effect of: We planned to use a random-effects model for all statistical analyses. For dichotomous variables we planned to calculate the treatment effect using a fixed-effect model and report it as a Peto odds ratio (OR) with 95% confidence interval (CI). For continuous data we planned to calculate the treatment effect using standardised mean differences (SMD) and 95% CI where different studies used different scales for the assessment of the same outcome, and using mean differences (MD) and 95% CI where studies all used the same method of measuring the outcome.
Unit of analysis issues
The primary outcome of functional ability in activities of daily living and secondary outcomes of functional ability in extended activities of daily living, eye movement data, balance, falls, depression and anxiety, and quality of life and social isolation comprise either ordinal data from measurement scales, count data, or continuous data. We planned to analyse these as continuous variables. If reported outcomes had a scale where a lower value is indicative of a better outcome (for example, a count of the number of falls, depression and anxiety scales), we multiplied the reported values by -1 so that in all analyses a higher value would be indicative of a better outcome. If studies reported change values these would be included with follow-up values in the meta-analysis, but we planned sensitivity analyses to investigate the effect of including these data. We planned to analyse discharge destination, adverse events, and death as dichotomous variables.
Dealing with missing data
If an included study did not report a particular outcome, we would not include that study in the analyses of that outcome. If an included study had missing data (for example, it reported the mean but not standard deviations for the follow-up data) we would take logical steps to enter an assumed value. Such steps might include estimating a standard deviation based on a reported standard error, or estimating a follow-up standard deviation based on a baseline value. We planned to do sensitivity analyses to investigate the effect of entering assumed values.
Assessment of heterogeneity
We planned to determine heterogeneity using the I 2 statistic. We would consider I 2 > 50% as substantial heterogeneity. If I 2 was less than or equal to 50% we would use a fixed-effect meta-analysis. If I 2 was greater than 50%, we would explore the individual trial characteristics to identify potential sources of heterogeneity, using pre-planned subgroup analyses.
Assessment of reporting biases
We attempted to avoid reporting biases by using a comprehensive search strategy that included searching for unpublished studies and searching trials registers. We planned to carry out sensitivity analyses to explore the effect of publication type.
Data synthesis
Two review authors (CH, AP) independently extracted data from the included trials. One review author (CH) entered the data into RevMan 5 (RevMan 2011) and the other review author (AP) checked the entries. They resolved any disagreements through discussion, with reference to the original report.
Subgroup analysis and investigation of heterogeneity
We intended to explore heterogeneity by subgroup analyses to investigate the effect of:
• age (under 60 years, 60 years and over);
• gender (male, female); • time after stroke (less than three months, less than six months, more than six months, at entry to study);
• type of eye movement disorder (III, IV, VI nerve palsy; reduced fixation or gaze holding; saccadic palsy or problems; smooth pursuit palsy or problems; strabismus; nystagmus; reduced convergence; conjugate deviation; skew deviation);
• deviation of eye movement (horizontal, vertical, torsional); • severity of eye movement disorder (slight, small, moderate, marked; paralysis and paresis; monocular and binocular);
• side of stroke (left, right); • presence of age-related visual problems (presence, absence); • presence of visual field impairment (presence, absence); • presence of visual inattention (presence, absence); • level of motor impairment (mild, moderate, severe); • level of cognitive impairment (mild, moderate, severe); • type of treatment (e.g. for compensative interventions: saccadic eye movement, activities of daily living training; for substitutive interventions: prisms, patches, environmental modifications; for assessment and screening: by orthoptist, occupational therapist, doctor).
We planned to use an established method for subgroup analyses (Deeks 2001). Prior to future updates of this review we will debate and reach consensus on the importance of these subgroup analyses, and we will consider reducing the number of planned subgroup analyses. For future updates we will carry out the planned subgroup analyses when there are six or more studies included in a single analysis, all with sufficient information to determine the subgroups.
Sensitivity analysis
We intended to carry out sensitivity analysis to explore the effect of the following methodological features.
• Allocation concealment: we planned to re-analyse data excluding trials with inadequate or unclear allocation concealment.
• Masking of outcome assessor: we planned to re-analyse data excluding trials without or with unclear masking of outcome assessor.
• Missing outcome data: we planned to re-analyse data excluding trials with inadequate or unclear methods of dealing with missing outcome data.
• Other bias: we planned to re-analyse data excluding trials assessed to have other bias or were unclear as to whether they had other bias.
• Publication type (peer-reviewed journal, conference abstract or proceedings, doctoral dissertation): we planned to re-analyse data including only those trials from peer-reviewed journals.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies; Characteristics of studies awaiting classification.
Results of the search
Our search strategy identified 7357 titles in the main databases. After elimination of duplicates and obviously irrelevant studies we were left with 1034 'possibly relevant' abstracts that covered all topics in this series of reviews: 373 related to visual field loss and disorders of eye movement. We obtained these 373 abstracts and two review authors (CC and CH) initially evaluated their inclusion according to the criteria described in the protocol. Where disagreement arose they sought the opinion of a third review author (AP). We assessed 81 abstracts as 'include' or 'unsure' for the visual field and eye movement disorders review and we obtained the full papers for these studies. Review by AP and CH of the full papers led to the inclusion in this review of two of these 81 studies. One of the 81 studies had inadequate information on the inclusion criteria and randomisation methods to classify it; contact with the authors has so far been unsuccessful. It has been added to the Characteristics of studies awaiting classification table. Where disagreements or uncertainties arose, we held consensus discussions involving additional authors where required. One review author (CH) conducted the wider search strategy, which involved databases of trials, commercial websites, hand-searching and cited reference searches. The final decision regarding inclusion of prospective studies was decided by discussion (CH and AP). We did not identify any further trials that could be included in the review; however, we identified one ongoing trial via www.clinicaltrials.gov. Two trials had to be investigated further, from www.clinicaltrials.gov and from the Cochrane Central Register of Controlled Trials (CENTRAL). Of these two trials, one was found to be ineligible and the other requires further clarification before a decision can be made. Their details are in the Characteristics of excluded studies table and Characteristics of studies awaiting classification table, respectively. Thus we identified a total of two studies for inclusion (Leigh 1991; Strupp 2003) . In addition, we identified one ongoing study (Rosner 2010) and two studies which are awaiting assessment ( Hofferberth 1995; Muchnick 1998).
Included studies
Two studies (28 randomised participants, five of whom were participants with stroke) met the inclusion criteria for this review (Leigh 1991; Strupp 2003) . Full descriptions of the studies can be found in the Characteristics of included studies table and in Table 1 (settings of included studies), Table 2 (demographics of included participants), and Table 3 (disorders of eye movements). A brief overview of the studies is presented below.
Study design
Both studies were randomised cross-over trials (Leigh 1991; Strupp 2003) . Both studies provided information on the procedures for randomisation and allocation concealment.
Interventions studied
The interventions studied by both included trials were systemic pharmacological interventions: Leigh 1991 compared trihexyphenidyl (5 mg capsules) with tridihexethyl chloride (25 mg capsules); Strupp 2003 compared 20 mg 3,4 diaminopyridine (DAP) plus lactose capsules with lactose-only capsules. We had not anticipated identifying trials of pharmacological interventions for eye movement disorders. Systemic pharmacological interventions were not, therefore, included within the classification of interventions (as restitution, compensation, substitution or assessment and screening interventions) proposed in the protocol. Following the protocol, review authors (CH, AP) independently attempted to categorise the systemic pharmacological interventions using the proposed classification system. Disagreement between these review authors led to a consensus discussion involving a further three expert reviewers (PL, BD, FR). Consensus could not be reached regarding the classification of the systemic pharmacological interventions using the protocol classification and it was agreed that an additional classification, pharmacological interventions, should be introduced.
Pharmacological interventions
Both studies investigated the effects of pharmacological interventions. In both of these studies the intervention was systemic drug treatment for nystagmus. One of the studies (Strupp 2003) compared the effect of a drug with a placebo intervention. The other (Leigh 1991) planned to compare the effect of the drug with a placebo. However, the planned placebo intervention was found to have an active effect on the outcomes measured, so this study was considered to compare the effect of two different pharmacological interventions.
Restitutive, compensative, or substitutive interventions
We found no trials investigating the effectiveness of restitutive, compensative or substitutive interventions.
Assessment and screening interventions
We found no trials investigating the effectiveness of assessment and screening interventions on relevant outcomes.
Studies included in comparisons within this review
One study (Strupp 2003) compared an active treatment with a control or placebo treatment. This study included only three participants whose eye movement disorder was caused by a stroke. The results from these patients were reported to be different from the other patients, which suggests that the response to the intervention in stroke patients may be different to the response of people with nystagmus not related to stroke. We chose not to include these data in a formal comparison as presentation of the results from this small group could prove misleading.
Populations studied
Both of the studies (Leigh 1991; Strupp 2003) included participants with nystagmus caused by mixed aetiologies including cerebellar atrophy, multiple sclerosis and post-surgical hypoxia. The percentage of stroke patients was: Leigh 1991, 20%; and Strupp 2003, 18%. Neither study noted the co-existance of any age-related eye problems, cognitive or motor problems. Both studies excluded participants with visual inattention, and Leigh 1991 also excluded participants with visual field loss.
Sample size
The sample sizes were two and three stroke patients in Leigh 1991 and Strupp 2003 respectively.
Outcome measures
Primary outcome
• Functional ability in activities of daily living. Neither of the included studies used a measure of functional ability.
Secondary outcomes
• Eye movement. Both trials measured aspects of the eye movements. Strupp 2003 used two-dimensional videooculography to record eye movements in horizontal and vertical directions. Leigh 1991 used the magnetic search coil technique to measure horizontal and vertical rotations, and an Amsler grid and video recording to measure eye movement during attempted fixation in the primary position and at 10 degrees horizontally and vertically.
• Adverse events. Strupp 2003 assessed adverse events by asking participants if they experienced side-effects 30 and 60 minutes after the intervention was administered.
Excluded studies
Reasons for the exclusion of studies that were initially thought to be relevant are provided in the table of Characteristics of excluded studies. We excluded one study (Repka 1989) because communication with the study author identified that patients with stroke were excluded from the study.
Risk of bias in included studies
Assessment of risk of bias for individual studies is described in the risk of bias tables in Characteristics of included studies and summarised in Figure 1 .
Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Allocation
Both studies were described as randomised double-blind cross-over trials and were assessed to have adequate allocation concealment.
Blinding
Both studies described that the drugs administered to both treatment groups were identical to look at. Strupp 2003 stated that masking was maintained until after data analysis was complete. Leigh 1991 did not give specific information about masking. However, since the interventions were administered as identical looking drugs, the review authors assumed that participants and outcome assessors were adequately masked to the intervention. Both studies were, therefore, assessed to have adequate blinding.
Incomplete outcome data
A number of participants dropped out of Leigh 1991 for a variety of reasons, including adverse events, leading the review authors assessment that this could be a potential source of bias. One participant was excluded from Strupp 2003; the review authors were uncertain of the impact of this and judged the risk of bias to be uncertain.
Other potential sources of bias
We judged both Leigh 1991 and Strupp 2003 unlikely to be at risk of other potential sources of bias. This assessment was based on an absence of information suggesting bias rather than the presence of information indicating that the studies were free of bias.
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Pharmacological interventions
We found insufficient evidence and data to carry out any analyses to explore the effect of pharmacological interventions compared with control or placebo interventions (see Included studies for details). Leigh 1991 reported a study that was designed as a placebo controlled trial comparing the anti-cholinergic 'active' drug trihexyphenidyl with the 'placebo' drug tridihexethyl chloride, which does not cross the blood-brain barrier. The authors report, based on pooled data from a cross-over study, that trihexyphenidyl was generally not effective in reducing the velocity of nystagmus. Trihexethyl chloride did have an effect, reducing nystagmus velocity in four out of six participants, but was associated with side-effects. Strupp 2003 reported that 3,4-diaminopyridine, a potassium channel blocker, had a significant effect on nystagmus velocity compared with a placebo (of lactose). However, this result was not found in the subgroup of stroke patients.
D I S C U S S I O N
Summary of main results
We found two studies which both investigated pharmacological interventions for disorders of eye movement in patients with stroke. The total number of included stroke patients was five. It was not appropriate to pool data and we were not able to draw conclusions from these studies. We found no other randomised studies that investigated interventions for disorders of eye movement in patients with stroke.
Overall completeness and applicability of evidence
Both identified studies investigated pharmacological interventions for the eye movement disorder of nystagmus. Strupp 2003 compared an active pharmacological intervention with an inactive placebo intervention, while Leigh 1991 was designed as a placebo control trial but was later determined to compare two different active pharmacological interventions. It was, therefore, not appropriate to combine the results within a meta-analysis. Both studies had a very small number of participants (total 38) and there were only a total of five participants with stroke. In the paper that compared the intervention to placebo (Strupp 2003), the results within the stroke subgroup were different to the patients with other aetiologies. This suggests that these patients may not respond to the treatment in the same way. This limits the evidence for the effectiveness of this intervention and its proposed mode of action in those patients with nystagmus following stroke. There is, therefore, clearly insufficient evidence from which to draw any conclusions relating to participants with stroke.
Quality of the evidence
We judged both included studies to have appropriate allocation concealment and blinding, and assessed neither to have 'other' potential sources of bias. However, Leigh 1991 reported a high dropout rate and we judged that incomplete outcome data were not addressed adequately. There was insufficient information to judge whether incomplete outcome data were appropriately addressed by Strupp 2003.
Potential biases in the review process Publication bias
Through a thorough searching process we are confident we should have identified all relevant published studies. However, it must be acknowledged that there is a possibility that there are additional studies (published and unpublished) that we did not identify. Many of the orthoptic journals were not included in the main databases of research journals covered by our search strategy; however these were handsearched by one review author (FR).
Categorisation of interventions
We had planned to categorise all interventions as either restitutive, substitutive, compensative or assessment and screening interventions. However, we had not anticipated the identification of pharmacological interventions when we developed these categories. We were unable to agree in which of the defined categories the pharmacological interventions should be included and, after discussion, we reached consensus that a new category was needed. As this decision did not alter any subsequent comparison or analysis we do not feel that this introduced bias into the review process.
Studies awaiting classification
We have identified one study (Hofferberth 1995), described as a controlled trial, which investigates saccadic eye movement training in 100 patients with stroke. We have been unable to contact the study authors to confirm if participants were randomised or not, although information in the published report suggests that the control group comprised 'healthy' participants. If this study is a RCT then this will contribute a substantial quantity of evidence to this review. Muchnick 1998 is a comparison study of surgical interventions for unilateral superior oblique muscle paresis. There are no data on the method of allocation nor on the cause of the paresis and thus it is not particularly likely to be relevant to this review. We have been unable to contact the study authors to clarify these issues.
Agreements and disagreements with other studies or reviews
Th Scottish Intercollegiate Guideline Network (SIGN) guidelines for stroke rehabilitation state that there is "almost no evidence relating to interventions for eye movement disorders" and was based on three reviews (Barrett 2009; Jones 2006; Riggs 2007), each of which had 'methodological limitations'. Neither the Barrett 2009 nor the Riggs 2007 review identified primary evidence relating to eye movement disorders in patients with stroke. Our review agrees with this finding as to the lack of evidence.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
There is insufficient evidence to reach conclusions about the effectiveness of interventions for patients with eye movement disorders after stroke.
Implications for research
There is currently an absence of relevant evidence. High-quality research is, therefore, urgently required.
Are randomised controlled trials required?
Randomised controlled trials (RCTs) are urgently required to determine the effects of clinically relevant rehabilitation interventions and pharmacological interventions in stroke patients compared to no treatment, placebo or usual care. We recommend that such RCTs must:
1. have adequate power (i.e. with an appropriate power calculation undertaken based on evidence from phase I and II studies); 2. have adequate allocation concealment, blinding of outcome assessor and intention-to-treat analysis;
3. clearly define trial participants; we recommend trials that include populations with the most common eye movement disorders of cranial nerve palsies, manifest strabismus, saccadic palsy and dysmetria, nystagmus and reduced convergence; 4. specifically recruit patients whose eye movement disorders are due to stroke; 5. include measures of functional ability in activities of daily living, visual function (including reading measures) and visionrelated quality of life; 6. report clear and usable data.
We recommend that future RCTs concentrate on answering the specific question relating to the effectiveness of interventions compared with control, placebo, no treatment or usual care rather than comparisons with variations of the same 'type' or category of intervention, or comparisons of different doses, adjuncts to treatment or modes of delivery. We believe that until such time as the benefits of interventions for eye movement disorders compared with control, placebo, no treatment or usual care have been established (or refuted) it is not beneficial to compare the relative effects of different interventions.
Are other primary research studies required?
Other primary research studies may be required in preparation for well-designed RCTs. In order to predict recruitment rates and plan future RCTs it would be useful to have clear information regarding the prevalence of eye-movement disorders within the stroke population at defined post-stroke time points.
Are further systematic reviews required?
We recommend that systematic reviews of RCTs of interventions for eye movement disorders with a neurological cause, but without a specific stroke aetiology, are carried out. There are a number of relevant RCTs and such systematic reviews may be used to support current management for individual patients in the absence of stroke-specific RCTs. There are already a number of Cochrane reviews synthesising the evidence from non-stroke populations, including reviews of botulinum toxin for the treatment of strabismus (Rowe 2009c) and adjustable versus non-adjustable sutures for strabismus (Haridas 2005). We recommend systematic reviews of non-randomised studies of interventions for eye movement disorders in patients with stroke in order to synthesise the current evidence base, to guide current practice, and to aid in the development of well-designed RCTs. Systematic reviews of evidence of the effectiveness of interventions for specific eye movement disorders in participants with mixed aetiologies may provide evidence which is relevant and transferable to the population of patients with eye movement disorders as a result of stroke. We recommend that this review is updated to identify and include any further RCTs. We did identify one ongoing study investigating prismatic spectacle lenses on symptoms of dizziness, headache and anxiety caused by vertical heterophoria. The researchers have confirmed that this study does include patients with stroke and it may therefore be relevant for future updates of this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Leigh 1991
Methods
Randomised double-blind cross-over trial Patients "randomly assigned", no further information available Notes Only 2 included participants had a stroke -of these only 1 actually took part in the trial, taking only tridihexethyl chloride Drug B (tridihexethyl chloride) was meant to be an active control, it is "an anti-cholinergic agent used for the treatment of peptic ulcer ... and ... would not be expected to cross the blood-brain barrier". However it was found to produce effects on the outcomes measured This was a cross-over trial, with participant changing to the other treatment after 1 to 2 weeks with no treatment 
Risk of bias
D A T A A N D A N A L Y S E S
This review has no analyses. 
A D D I T I O N A L T A B L E S
A P P E N D I C E S Appendix 1. CENTRAL (The Cochrane Library) search strategy
To avoid duplication of effort we designed broad search strategies for the major databases sensitive enough to cover the scope of a series of three Cochrane reviews of interventions for different visual disorders following stroke. We devised the following search strategy, using a combination of controlled vocabulary (MeSH) and free text terms, for MEDLINE and modified it to suit other databases: MEDLINE (Appendix 2); EMBASE (Ovid) (Appendix 3); CINAHL (EBSCO) (Appendix 4); AMED (Ovid) (Appendix 5); PsycINFO (Ovid) (Appendix 6). 13 . stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or apoplex* or SAH 14. (brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch?emi* or infarct* or thrombo* or emboli* or occlus*) 15. (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed*) 16 
